The report provides an in-depth analysis of fungicides consumption in different types of crops such as cereal &grains, oilseed &pulses, fruits &vegetables, and others. It also provides the production of different types of fungicides such as dithiocarbamates, benzimidazoles, chloronitriles, triazoles, phenylamides, strobilurins, and others. The other fungicides include morpholines and anilinopyrimidines. The market analysis and estimations are done in terms of revenue and volume of the fungicides. The report provides information on revenues and volume of production for all geographies, types of fungicides, and types of crops. The revenue of global fungicides includes the revenues of synthetic fungicides and biofungicides.

One of the major factors driving the growth of the companion diagnostic market is the increasing demand for personalized medicines and awareness about the same among the population. With companies increasing their collaborations for better biomarkers and diagnostics to focus on cost regulations, there have been significant number of oppor tunities for their application in indications other than in cancer, like cardiovascular and neurological. The high rise in capital is the basis for the prosperous future of this market. Companion diagnostics is becoming an indispensable part of personalized medicine and is expected to gain prominence in therapeutics used for the treatment of various diseases. The use of companion diagnostics is taking up a central role as an important treatment decision tool for a number of oncology drugs, and it is also reflected in the way the FDA classifies these assays in relation to risk. In the United States, companion diagnostics assays are classified as IVD class III products, representing a highrisk category, and consequently the highest level of regulatory control.

The report provides dynamics and trends related to the global clinical nutrition market. In addition, it presents the estimations and forecast of the market. Moreover, the study estimates revenue generated from the sales of clinical nutrition products. The revenues are confined to the clinical nutrition options to maintain health. These products aid to improve the metabolic system of the body by providing adequate supplements such as minerals, vitamins, and others.

Biomarker can be defined as a naturally occurring gene, molecule, or a characteristic that can be quantitatively analyzed and assessed as an indicator of a pathogenic, normal biological, or a pharmacological response to a therapeutic intervention. Biomarkers are identified by diagnostic processes, assays, and certain interventions. Any anomaly identified in the biomarker indicates the presence of a disease such as cancer; thus, this process can be quantified and interrelated with disease, health, or drug treatment. The cancer biomarkers market report covers revenue generated from sales of instruments used in cancer biomarker diagnostic procedures. However, applications of cancer biomarkers in research, clinical trials, drug development, drug validation, risk assessment, and drug formulation are excluded from the scope of this report. The report also excludes revenue generated from services provided by physicians in the cancer biomarker diagnostics procedures.

The current market for cervical cancer diagnostics is growing at a healthy rate, which is primarily attributed to the increasing involvement of the government organizations in cervical cancer screening programs and increasing burden of the disease across the world. PAP and HPV tests are vital for diagnosis of cervical cancer. Mostly these tests are performed together for the patient age group between 21-65 years. As per the International Agency for Research on Cancer, more than 85% of cervical cancers patients are from the developing countries, which demands better efficacy screening and treatment programs for women health. Since the cancer progression is slow and may take up to 20 years to develop into an advanced stage, there are many opportunities to stop the disease before it becomes fatal. At present, there are many cities in the emerging market that lack resources for a good laboratory with highly trained cytotechnicians and other specialized staff, which is among the major challenge for good results from Pap testing. With the advancement in HPV tests, the possibility of preventing the cervical cancer has increased even in the low-resource countries (developing countries) because HPV tests are becoming more affordable. Along with that, cost-effective strategies are being implemented by the countries to leverage self-sampling.

Biocides are products or chemicals that combat pests or microorganisms. These are generally used to control and kill harmful and unwanted organisms such as mold, bacteria, algae, insects, and rodents. Biocides represent various products such as disinfectants, wood preservatives, rodenticides, antifouling agents (on boats), in-can preservatives, used in homes, public places such as hospitals, and industries. Biocide preservation applications are leading the market, accounting for the largest consumption of specialty biocides in both volume and value terms. Despite regulatory pressures, reducing the number of biocides depending on their concentrations in end products, blends of carefully selected biocidal active substances in optimal ratios, coupled with new technical advancements can provide improved preservation solutions without the need for cautionary labeling.

The dengue testing market is currently showing a healthy growth due to the increase in incidences of dengue cases. Change in climate is likely to increase the burden of dengue fever further. In addition, increasing awareness campaigns to educate about the ills of dengue are boosting the market growth. The overall incidence of dengue, as well as the explosive outbreaks of dengue, has been increasing dramatically over the past several years. According to the World Health Organization, the number of cases reported increased from 2.2 million in 2010 to over 3.34 million in 2016, and it is still on the rise. Although the full global burden of the disease is uncertain, the initiation of activities to record all dengue cases par tly explains the sharp increase in the number of cases repor ted in recent years. Therefore, not only the number of cases is increasing as the disease spreads to new areas, but better diagnostics and documentation of outbreaks is occurring as well.

The dental sterilization market is primarily driven by increasing prevalence of dental ailments, such as edentulism, dental caries, and others coupled with the rising demand for cosmetic dentistry owing to its broadening applications. In dentistry, it is very important to have an effective and efficient way of controlling any type of infection, in order to ensure the patient’s wellbeing. Disinfection and sterilization are essential to prevent transmission of infectious pathogens to patients and staff. There are number of programs on infection control that spread awareness about sterilization and cleaning of dental devices and instruments. According to the Global Burden of Disease Study estimates, in 2017, oral diseases affected arounnd 3.5 billion people worldwide, with caries of permanent teeth being the most common condition. globally.

在中国，与冠状动脉的介入治疗相比，外周血管介入治疗方案进入中国的时间显著晚于冠状动脉介入治疗，外周血管治疗市场在我国仍处于发展早期。目前我国外周血管疾病治疗率低，以外周动脉治疗率而言只有0.2%的患者接受了血运重建治疗，静脉的治疗率相对更低。未来随着中国居民生活水平提高，健康意识增强，外周血管疾病的治疗率会逐步提升。

医药板块2019年中报前瞻，上半年业绩分化，二季度环比改善。我们对覆盖的27家重点公司2020年中报业绩进行前瞻分析，其中12家已发布业绩预告或业绩快报。整体看受国内外新冠疫情影响，相关公司中报业绩分化较为明显：部分公司利润大幅增长、部分公司明显下滑；但总体看，绝大部分公司二季度经营情况环比一季度均有明显改善。这意味着疫情对医药板块经营情况的负面影响已基本结束，下半年有望继续保持改善回升的势头。